中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2015年
8期
696-699
,共4页
糖尿病,2型%色素上皮衍生因子%二肽基肽酶-4抑制剂
糖尿病,2型%色素上皮衍生因子%二肽基肽酶-4抑製劑
당뇨병,2형%색소상피연생인자%이태기태매-4억제제
Diabetes mellitus,type 2%Pigment epithelium-derived factor%Dipeptidyl peptidase-4 inhibitors
为了解2型糖尿病患者血清色素上皮衍生因子( PEDF)水平以及予以二肽基肽酶-4抑制剂利格列汀治疗前后PEDF的变化,进一步探讨PEDF与血脂、体重指数、HbA1C等指标相关性。选取39例新诊断2型糖尿病患者和30名健康者进入研究。常规检测2组受试者体重、腰围、体重指数、空腹血糖、HbA1C、血清谷丙转氨酶、谷草转氨酶、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇指标,采用酶联免疫吸附法检测血清PEDF的浓度。2型糖尿病组予口服利格列汀5 mg/d治疗6个月,6个月后再次检测血清PEDF浓度和临床指标,并进行统计学分析。结果显示：(1)治疗前2型糖尿病组血清PEDF浓度与对照组相比浓度相似(P=0.584),PEDF与低密度脂蛋白胆固醇、腰围呈正相关(P<0.05或P<0.01)。(2)经利格列汀治疗6个月后2型糖尿病组血清PEDF水平较治疗前增加,差异具有统计学意义[(3.21±1.91对2.45±1.53)μg/ml, P<0.01]。2型糖尿病患者血清PEDF水平与对照组相似,与低密度脂蛋白胆固醇、腰围相关,经利格列汀治疗后血清PEDF水平上升,提示利格列汀可能对糖尿病血管并发症有一定保护作用。
為瞭解2型糖尿病患者血清色素上皮衍生因子( PEDF)水平以及予以二肽基肽酶-4抑製劑利格列汀治療前後PEDF的變化,進一步探討PEDF與血脂、體重指數、HbA1C等指標相關性。選取39例新診斷2型糖尿病患者和30名健康者進入研究。常規檢測2組受試者體重、腰圍、體重指數、空腹血糖、HbA1C、血清穀丙轉氨酶、穀草轉氨酶、總膽固醇、甘油三酯、高密度脂蛋白膽固醇、低密度脂蛋白膽固醇指標,採用酶聯免疫吸附法檢測血清PEDF的濃度。2型糖尿病組予口服利格列汀5 mg/d治療6箇月,6箇月後再次檢測血清PEDF濃度和臨床指標,併進行統計學分析。結果顯示：(1)治療前2型糖尿病組血清PEDF濃度與對照組相比濃度相似(P=0.584),PEDF與低密度脂蛋白膽固醇、腰圍呈正相關(P<0.05或P<0.01)。(2)經利格列汀治療6箇月後2型糖尿病組血清PEDF水平較治療前增加,差異具有統計學意義[(3.21±1.91對2.45±1.53)μg/ml, P<0.01]。2型糖尿病患者血清PEDF水平與對照組相似,與低密度脂蛋白膽固醇、腰圍相關,經利格列汀治療後血清PEDF水平上升,提示利格列汀可能對糖尿病血管併髮癥有一定保護作用。
위료해2형당뇨병환자혈청색소상피연생인자( PEDF)수평이급여이이태기태매-4억제제리격렬정치료전후PEDF적변화,진일보탐토PEDF여혈지、체중지수、HbA1C등지표상관성。선취39례신진단2형당뇨병환자화30명건강자진입연구。상규검측2조수시자체중、요위、체중지수、공복혈당、HbA1C、혈청곡병전안매、곡초전안매、총담고순、감유삼지、고밀도지단백담고순、저밀도지단백담고순지표,채용매련면역흡부법검측혈청PEDF적농도。2형당뇨병조여구복리격렬정5 mg/d치료6개월,6개월후재차검측혈청PEDF농도화림상지표,병진행통계학분석。결과현시：(1)치료전2형당뇨병조혈청PEDF농도여대조조상비농도상사(P=0.584),PEDF여저밀도지단백담고순、요위정정상관(P<0.05혹P<0.01)。(2)경리격렬정치료6개월후2형당뇨병조혈청PEDF수평교치료전증가,차이구유통계학의의[(3.21±1.91대2.45±1.53)μg/ml, P<0.01]。2형당뇨병환자혈청PEDF수평여대조조상사,여저밀도지단백담고순、요위상관,경리격렬정치료후혈청PEDF수평상승,제시리격렬정가능대당뇨병혈관병발증유일정보호작용。
[Summary] To investigate the difference in serum pigment epithelium-derived factor ( PEDF) among type 2 diabetic patients before and after use of dipeptidyl peptidase-4 inhibitors linagliptin for treatment, and to explore the correlation of serum PEDF with lipids, body mass index, and HbA1C . 39 patients with recently diagnosed type 2 diabetes and 30 healthy individuals were enrolled. Baseline weight, waist circumference, body mass index, fasting plasma glucose, HbA1C , serum glutamic-pyruvic transaminase, glutamic oxaloacetic transaminase, total cholesterol, triglyceride, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol ( LDL-C) , and PEDF measured by enzyme linked immunosorbant assay were determined both in the diabetic and control subject. The treatment group was treated with oral linagliptin 5 mg/d for six month, serum PEDF and clinical parameters were determined in the diabetic group during 6 months of treatment. ( 1 ) PEDF levels were found to be comparable with the controls ( P=0. 584);LDL-C and waist circumference showed positive correlation with PEDF(P<0. 05 or P<0. 01). (2) PEDF level was significantly increased in patients with type 2 diabetes after linagliptin treatment [(3. 21 ± 1. 91 vs 2. 45 ± 1.53)μg/ml,P<0.01]. SerumPEDFlevelinpatientswithtype2diabeteswassimilartothatofhealthycontrolswith associated LDL-C and waist circumference. After linagliptin treatment, serum PEDF level was raised, suggesting that it may have certain protective effect for diabetic vascular complications.
